Anti-PD1 antibody [SPM597] - BSA and Azide free,Abcam,AB269805

ab269805 is a carrier free version of ab218474 . Conjugation ready Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. Compatibility This product is compatible with the Maxpar ® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar ® is a trademark of Fluidigm Canada Inc.

Host

Mouse

Reactivity

Human

Application

IHC-P

Platform ID

BAB730449889

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-PD1 antibody [SPM597] - BSA and Azide free
Cat. No.AB269805
HostMouse
IsotypeIgG1
ReactivityHuman
ApplicationIHC-P
ClonalityMonoclonal
Clone NumberSPM597
Concentration1 mg/mL Batch dependent concentration
ImmunogenRecombinant Full Length Protein corresponding to Human PDCD1.
PurityAffinity purification Protein G
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Constituents: PBS
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data The protein expressed by the gene PDCD1 functions as an inhibitory receptor on antigen-activated T-cells, playing a critical role in the induction and maintenance of immune tolerance to self. It delivers inhibitory signals by binding to the ligands CD274/PDCD1L1 and CD273/PDCD1LG2. Tumors exploit the PDCD1-mediated inhibitory pathway to attenuate anti-tumor immunity, enabling tumor survival by evading immune system destruction. The interaction with CD274/PDCD1L1 inhibits the effector function of cytotoxic T lymphocytes (CTLs). Blocking the PDCD1-mediated pathway can reverse the exhausted T-cell phenotype and normalize the anti-tumor response, providing a rationale for cancer immunotherapy. This supplementary information is collated from multiple sources and compiled automatically. See full target information PDCD1

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.